ReviewPregnancy (Hoboken, N.J.)2025
Antenatal medication management for women with sickle-cell disease: A systematic review.
Review in Pregnancy (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- New WHO recommendations on the management of sickle-cell disease in pregnancy.Pregnancy (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Improvements in sickle-cell disease (SCD) treatment have led to an increasing number of individuals surviving to reproductive age. However, pregnancy in women with SCD carries a heightened risk of maternal and fetal complications. Objective: To evaluate the effectiveness and safety of commonly used antenatal medications and transfusion strategies on maternal and neonatal outcomes in pregnant women with SCD. Methods: A systematic review was conducted using a pre-registered protocol (PROSPERO: CRD42023484839). Comprehensive literature searches were performed in PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Scopus, Embase, and CINAHL from their inception to November 24, 2023. Eligible studies included randomized controlled trials (RCTs), cluster RCTs, quasi-experimental studies, prospective and retrospective cohort studies, case-control studies, interrupted time series, and controlled before-and-after studies. Included studies examined antenatal medication or transfusion strategies for pregnant women with SCD, including any genotype. Risk of bias was assessed using RoB 2 for RCTs and ROBINS-I for non-randomized studies (NRSIs). Certainty of RCT evidence was evaluated using GRADE criteria. Data were synthesized using narrative synthesis due to study heterogeneity. Results: A total of 23 studies were included, of which two were RCTs and 21 were NSRIs. The RCTs investigated prophylactic transfusion and iron supplementation. Prophylactic transfusion may reduce the risk of sickle-cell crisis but the effect on other maternal or neonatal outcomes is unclear due to very low-certainty evidence. The effect of iron supplementation on maternal and neonatal outcomes is also of very low certainty. The observational studies carried a high risk of bias preventing meta-analysis and limiting the ability to draw conclusions. Conclusions: There is a limited body of evidence on antenatal medication and transfusion management strategies for pregnant women with SCD. High-quality studies are needed to inform evidence-based antenatal care for this population. Trial Registration: PROSPERO: CRD 42023484839.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.